
SUMMARY


[0004] Provided herein are methods of treating depression, e.g., major depressive disorder, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the formula



(Compound 1)

or a pharmaceutically acceptable salt thereof. In further examples, Compound 1 is administered using an episodic dosing regimen. In the methods described herein, Compound 1 or a pharmaceutically acceptable salt thereof can be administered for a specified period of time, e.g., 14 days. Following such specified periods of time, the subject is not dosed with the compound for another specified period of time, e.g., at least a period of e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, or about 6 weeks.


[0004a] In one aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days.


[0004b] In another aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days.


[0004c] In a further aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days and about 30 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.


[0004d] In another aspect of the present disclosure, there is provided a use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days and about 50 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

[0005] In one example, described herein is a method of treating depression, e.g. major depressive disorder (MDD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount, e.g., about 30 mg, of a compound of the formula:




(Compound 1)

once a day for 14 days. In another example, described herein is a method of treating depression, e.g. major depressive disorder (MDD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount, e.g., about 50 mg, of Compound 1 once a day for 14 days. In some examples, the therapeutically effective amount of the compound is 30 mg-40 mg. In some examples, the therapeutically effective amount of the compound is 30 mg-50 mg. In some examples, the therapeutically effective amount of the compound is 40 mg-60 mg. In some examples, the therapeutically effective amount of the compound is 45 mg-55 mg. In some examples, the therapeutically effective

amount of the compound is 30 mg. In some examples, the therapeutically effective amount of the compound is 50 mg. In some examples, the major depressive disorder is severe major depressive disorder (SMDD). In some examples, the subject exhibits a reduction in depression-related symptoms. In some examples, the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment. In some examples, the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.

[0006] In another example of the methods provided herein, described herein is a method of treating depression, e.g. major depressive disorder, comprising the steps of:

(i) administering once daily to the subject a therapeutically effective amount, e.g., about 30 mg, of a compound of the formula:




(Compound 1)

once a day for 14 days; and

(ii) re-administering once daily to the subject a therapeutically effective amount, e.g., about 30 mg, of Compound 1 for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

[0007] In another example of the methods provided herein, described herein is a method of treating depression, e.g. major depressive disorder, comprising the steps of:

(i) administering once daily to the subject a therapeutically effective amount, e.g., about 50 mg, of a compound of the formula:



(Compound 1)

once a day for 14 days; and

(ii) re-administering once daily to the subject a therapeutically effective amount, e.g., about 50 mg, of Compound 1 for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

[0008] In some examples, the therapeutically effective amount of the compound is 20 mg-40 mg. In some examples, the therapeutically effective amount of the compound is 20 mg-50 mg. In some examples, the therapeutically effective amount of the compound is 40 mg-60 mg. In some examples, the therapeutically effective amount of the compound is 45 mg-55 mg. In some examples, the therapeutically effective amount of the compound is 30 mg. In some examples, the therapeutically effective amount of the compound is 50 mg. In some examples, the major depressive disorder is severe major depressive disorder. In some examples, the subject exhibits a reduction in depression-related symptoms. In some examples, the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment. In some examples, the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment. In some examples, the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.

BRIEF DESCRIPTION OF THE DRAWINGS


[0009] FIG. 1 depicts an exemplary study design for treating MDD with Compound 1.

[00010] **FIG. 2** depicts exemplary HAM-D total score LS mean changes from baseline to Day 15 in patients in a Phase 3 study of Compound 1 in Major Depressive Disorder.

CLAIMS

What is claimed is:


1. Use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days.

2. Use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days.

3. The use of claim 1 or 2, wherein the major depressive disorder is severe major depressive disorder.

4. The use of any one of claims 1-3, wherein the subject exhibits a reduction in depression-related symptoms.

5. The use of any one of claims 1-4, wherein the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline.

6. The use of any one of claims 1-5, wherein the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment.


7. The use of any one of claims 1-6, wherein the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment.

8. The use of any one of claims 1-7, wherein the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment.

9. The use of any one of claims 1-8, wherein the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment.

10. The use of any one of claims 1-9, wherein the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.


11. Use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 40 mg of said compound is to be administered to the subject once a day for 14 days and about 30 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

12. Use of a compound of the formula:



(Compound 1)

in the manufacture of a medicament for treating major depressive disorder in a subject in need thereof, wherein about 50 mg of said compound is to be administered to the subject once a day for 14 days and about 50 mg of Compound 1 is to be re-administered once daily to the subject for 15 days in response to a recurrence of depression symptoms, provided there is at least a 6 week interval between administration of Compound 1 to the subject and re-administration of Compound 1 to the subject.

13. The use of claim 11 or 12, wherein the major depressive disorder is severe major depressive disorder.

14. The use of any one of claims 11-13, wherein the subject exhibits a reduction in depression-related symptoms.

15. The use of any one of claims 11-14, wherein the reduction in depression-related symptoms is characterized by a reduction in HAM-D score from baseline.

16. The use of any one of claims 11-15, wherein the major depressive disorder is characterized by a HAM-D score of at least 22 prior to treatment.

17. The use of any one of claims 11-16, wherein the major depressive disorder is characterized by a HAM-D score of at least 24 prior to treatment.

18. The use of any one of claims 11-17, wherein the major depressive disorder is characterized by a HAM-D score of at least 25 prior to treatment.

19. The use of any one of claims 11-18, wherein the major depressive disorder is characterized by a HAM-D score of at least 26 prior to treatment.

20. The use of any one of claims 11-19, wherein the major depressive disorder is characterized by a MADRS score of at least 32 prior to treatment.